Fungal Infection

  • Takashi Mochizuki

Key Features

  • Superficial fungal infection is the most prevalent skin disease.

  • Detection of the pathogen from a lesion by mycological tests is essentially important.

  • Superficial infections are usually successfully treated with topical antimycotics.

  • Onychomycoses and hair infections require oral antimycotics.


Tinea Capitis Tinea Pedis Tinea Corporis Superficial Fungal Infection Tinea Cruris 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Elewski BE (2000) Tinea capitis: a current perspective. J Am Acad Dermatol 42:1–20PubMedCrossRefGoogle Scholar
  2. 2.
    Andre J, Achten G (1987) Onychomycosis. Int J Dermatol 26:481–490PubMedCrossRefGoogle Scholar
  3. 3.
    Shiraki Y, Hiruma M, Hirose N, Sugita T, Ikeda S (2006) A nationwide survey of Trichophyton tonsurans infection among combat sport club members in Japan using a questionnaire form and the hairbrush method. J Am Acad Dermatol 54:622–626PubMedCrossRefGoogle Scholar
  4. 4.
    Fleckman P (2002) Onychomycosis:diagnosis and topical therapy. Dermatol Ther 15:71–77CrossRefGoogle Scholar
  5. 5.
    Watanabe S, Seki Y, Shimozawa M, Takizawa K (1983) Nail candidiasis. J Dermatol 10:189–203PubMedGoogle Scholar
  6. 6.
    Tosti A, Piraccini BM, Lorenzi S (2000) Onychomycosis caused by nondermatophytic molds,: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 42:217–224PubMedCrossRefGoogle Scholar
  7. 7.
    Vander Straten MR, Balkis MM, Ghannoum MA (2002) The role of nondermatophyte molds in onychomycosis:diagnosis and treatment. Dermatol Ther 15:89–98CrossRefGoogle Scholar
  8. 8.
    Ninomiya J, Ito Y, Takiuchi I (2005) Evaluation of the effi-cacy of miconazole nitrate shampoo for prevention against T. tonsurans infection. Jpn J Med Mycol 46:177–181CrossRefGoogle Scholar
  9. 9.
    Evans EG, Sigurgeirsson B (1999) The L.I.O.N. study group:Double blind, randomised study of continuous terbin-afine compared with intermittent itraconazole in treatment of toenail onychomycosis. BMJ 318:1031–1035PubMedCrossRefGoogle Scholar
  10. 10.
    Sigurgeirsson B, Olafsson JH, Steinsson J, Paul C, Billstein S, Evans EGV (2002) Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. Arch Dermatol 138: 353–357PubMedCrossRefGoogle Scholar
  11. 11.
    Evans EG (1994) A comparison of terbinafine(Lamisil) 1% cream given for one week with clotrimazole(Canesten)1% cream given for four weeks in treatment of tinea pedis. Br J Dermatol 130(suppl 43):12–14PubMedCrossRefGoogle Scholar
  12. 12.
    Watanabe S, Takahashi H, Nishikawa T, Takiuchi I, Higashi N, Nishimolto K, Kagawa S, Yamaguchi H, Ogawa H (2006) A comparative clinical study between 2 weeks of lulicon-azole 1% cream treatment and 4 weeks of bifonazole 1% cream treatment for tinea pedis. Mycoses 49:236–241PubMedCrossRefGoogle Scholar
  13. 13.
    Terbinafine Study Group (1994) Clinical evaluation of oral terbinafine, newly developed antimicotic agent, in patient with onychomycosis— a dose finding study. Nishinihon J Dermatol 56:129–143 (in Japanese)Google Scholar
  14. 14.
    Huang DB, Ostrosky-Zeichner L, Wu JJ, Pang KR, Tyring SK (2004) Therapy of common superficial fungal infections. Dermatol Ther 17:517–522PubMedCrossRefGoogle Scholar
  15. 15.
    Morishita N, Yamazaki K, Ninomiya J, Hamaguchi T, Sei Y, Takiuchi (2001) A case of lymphocutaneous sporotrichosis. Jpn J Med Mycol 42:149–154CrossRefGoogle Scholar
  16. 16.
    Sterling JB, Heymann WR (2000) Potassium iodide in dermatology: a 19th century drug for the 21st century-uses, pharmacology, adverse effects, and contraindications. J Am Acad Dermatol 43:691–697PubMedCrossRefGoogle Scholar
  17. 17.
    Brandt ME, Warnock DW (2003) Epidemiology, clinical manifestations and therapy of infections caused by dematia-ceous fungi. J Chemother 15(suppl 2):36–47PubMedGoogle Scholar
  18. 18.
    Tagami H, Ginoza M, Imazumi S, Urano-Suehira S (1984) Successful treatment of chromoblastomycosis with topical heat therapy. J Am Acad Dermatol 10:615–619PubMedCrossRefGoogle Scholar
  19. 19.
    Gupta AK, Taborda PR, Sanzovo AD (2002) Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol 40:529–534PubMedGoogle Scholar
  20. 20.
    Kondo M, Hiruma M, Nishioka Y, Mayuzumi N, Mochida K, Ikeda S, Ogawa H (2005) A case of chromomycosis caused by Fonsecaea pedrosoi and a review of reported cases of dematiaceous fungal infection in Japan. Mycoses 48:221–225PubMedCrossRefGoogle Scholar
  21. 21.
    Christianson JC, Engber W, Andes D (2003) Primary cutaneous cryptococcosis in immunocompetent and immuno-compromised hosts. Med Mycol 41:177–188PubMedCrossRefGoogle Scholar
  22. 22.
    Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE (2000) Practice guidelines for the management of cryptococcal disease. Infectious diseases society of America. Clin Infect Dis 30:710–718PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2010

Authors and Affiliations

  1. 1.Department of DermatologyKanazawa Medical UniversityKahokuJapan

Personalised recommendations